Sara HernandoUniversidad del País Vasco / Euskal Herriko Unibertsitatea | UPV/EHU
Sara Hernando
Doctor of Pharmacy
About
9
Publications
1,684
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
279
Citations
Introduction
Additional affiliations
May 2021 - July 2021
January 2021 - May 2021
February 2021 - May 2021
Education
January 2017 - December 2020
Field of study
- Pharmacy and Pharmaceutical Technology
September 2010 - July 2015
Publications
Publications (9)
Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD) and Parkinson's disease (PD) are an accelerating global health problem as life expectancy rises worldwide. Despite their significant burden in public health systems to date, the existing treatments only manage the symptoms without slowing down disease progression. Thus, the ongoing n...
Background aims:
Despite intensive research, to date, there is no effective treatment for neurodegenerative diseases. Among the different therapeutic approaches, recently, the use of extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) has gained attention.
Methods:
In the present work, we focused on medium/large extracellu...
Background
Neurodegenerative diseases (NDs) are an accelerating global health problem. Nevertheless, the stronghold of the brain- the blood–brain barrier (BBB) prevents drug penetrance and dwindles effective treatments. Therefore, it is crucial to identify Trojan horse-like drug carriers that can effectively cross the blood–brain barrier and reach...
Neurodegenerative diseases (ND) are one of the main problems of public health systems in the 21st century. The rise of nanotechnology-based drug delivery systems (DDS) has become in an emerging approach to target and treat these disorders related to the central nervous system (CNS). Among others, the use of nanostructured lipid carriers (NLCs) has...
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been widely associated to beneficial effect over different neurodegenerative diseases. In the present study, we tested the potential therapeutic effect of docohexanoic acid (DHA) and its hydroxylated derivate, DHAH, in a partial lesion model of Parkinson's disease (PD). One month before and four...
Nanomedicine is a field of science that employs materials in the nanometer scale. Specifically, the use of nanoparticles (NPs) has some medical applications due to their structure, for example, the ability to cross the biological barriers, and their effectiveness avoiding some drug delivery problems. Because of that, in the last years, the use of N...
Parkinson’s disease (PD) is the second most common neurodegenerative disorder (ND), characterized by the loss of dopaminergic neurons, microglial activation, and neuroinflammation. Current available treatments in clinical practice cannot halt the progression of the disease. During the last few years, growth factors (GFs) have been raised as a promi...
Nanotechnology has been raised as a promising alternative for the diagnosis and treatment of different neurodegenerative disorders (ND). Among NDs, Alzheimer’s disease (AD) and Parkinson’s disease (PD) represent the most common neurodegenerative disorders worldwide. The early diagnoses of AD and PD together with a successful treatment hampering the...
Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators h...
Questions
Questions (4)
I have performed an immunostainning in rat brain brain cortex in order to see new blood vessels formation. In order to cuantify it, I have densitometered the images following these steps in ImageJ
1. Image>type>8-bit
2. Select area of interest
3. Add selection: image>overlay>add selection
4. Image>overlay>To ROI manager
5. Measure; area and grey intensity.
Then the grey intensity/area= IOD
Am I following the correct steps? Is there any other method to measure angiogenesis in rat brain cortex?
Thank you!
Sara
Hi everybody, I'm trying to obtain microglia purification from rat pupets from 1-3 days. After having the glia culture for two weeks, I tried to purify the microglia following this protocol https://bio-protocol.org/e314.
To assure I have only microglia cells I performed an immunofluoresnce assay with the following protocol.
1. Retire cell medium
2. Wash with PBSx2
3. Fix cells with PFA 4%
4. Wash with PBSx3
5. Blocking and permebilization with BSA0,1%, Triton 0,1% in PBS for 2h, RT
6. Wash with PBSx3
7. Incubate primary antibodys (rabbit polyclonal Iba1, synaptic systems # 234 003 and goat polyclonal GFAP, Abcam # ab53554) with BSA0,1%, Triton 0,1% in PBS, ON at 4ºC
8.Wash with PBSx3
9. Incubate with secondary antibodys (Alexa 488 anti rabbit, Alexa 555 Anti goat), with BSA0,1%, Triton 0,1% in PBS fo 2h, RT
10.Wash with PBSx3
11. Incubate con DAPI
12. Mounted and coverslipped
The images I obtained with the microscope are the following. (A) In the green lut I cannot see specificty for Iba1+ cells, since I see also astrocytes. How can I improve the specicifity for this antibody? Should I perfomer the IF with order antibody to mark microglia cells? In the red lut I can also see some Iba1 cells but I think that this is autofluorescence, am I okey? (B) Microglia cells in brieghtfield. (C) Glia mixed ulture in brieghtfiled before purification. The images obatined in brightfield (B) are microglia cells for sure?
Thank you! :)
Hi! I have purchased Nrf2 Abcam antibody (ab31163). I want to perform an inmunohistochemistry in paraformaldehyde fixed rat brain sections. I have not clear which protocol should I follow, inmunofluorescence with Alexa 488 as secondary antibody or another IHC protocol with DAB visualization. Is it neccesary antigen retrieval for any of this protocols?
Thank you in advanced ;)
Sara
Hi! I have perform cylinder test in 6-OHDA animal model of PD to test the neuroprotective effect of one drug. I have obtained good results measuring the number of impaired forelimb wall contacts. Apart form this, I realize that there is a tendency in the time they spent in the cylinder until the 20 touches, being significantly less for the group tretated with the drug. That is why I was wondering if I can use thses results to explain the effect of the drug on the cognition and/or anxiety, as if I had done an open field, T-maze or elevated plus maze test.
Thank you in advanced!
Sara.
